Skip to Main Content
Table 2.

SIR for second malignant neoplasm by primary cancer diagnosis

Primary cancer diagnosisTime to SMN (years)
TypeTotalSIR (95% CI)Mean (SD)Median (rangea)
Total for all cancers 7,920 9.9 (8.6–11.4) 8.6 (6.0) 7.3 (0.0–24.9) 
Leukemia 2,428 8.4 (6.1–10.9) 8.9 (6.2) 8.3 (0.3–22.7) 
 Acute lymphoblastic 1,944 7.7 (5.4–10.4) 9.1 (6.2) 8.3 (0.3–22.7) 
 Acute myeloid 363 8.6 (2.7–17.7) 10.8 (6.2) 10.8 (2.2–17.5) 
 Other 121 20.2 (6.4–41.7) 5.4 (6.3) 3.5 (0.6–16.3) 
Lymphoma and reticuloendothelial 1,044 11.3 (7.8–15.3) 10.0 (7.0) 11.6 (0.0–23.8) 
 Hodgkin lymphoma 317 15.7 (9.4–23.5) 12.6 (6.1) 12.6 (2.1–23.8) 
 Non-Hodgkin lymphoma 437 12.1 (6.4–19.6) 7.6 (7.4) 3.0 (1.2–21.2) 
 Other 290 3.6 (0.7–8.9) 3.8 (3.6) 4.2 (0.0–7.1) 
CNS 1,897 9.6 (6.9–12.7) 8.7 (5.2) 8.9 (0.3–20.3) 
 Astrocytoma 706 6.1 (3.1–10.0) 11.0 (5.5) 11.5 (1.6–20.3) 
 Medulloblastoma 316 16.8 (7.2–30.4) 5.4 (4.4) 3.9 (1.5–14.8) 
 Other CNS 875 11.4 (7.1–16.9) 8.5 (4.7) 9.2 (0.3–18.8) 
Sympathetic nervous system 748 11.2 6.3–17.6) 8.4 (5.7) 5.6 (1.3–18.2) 
 Neuroblastoma 542 15.1 (8.0–24.4) 9.0 (5.9) 6.2 (1.3–18.2) 
 Retinoblastoma 205 4.2 (0.4–12.1) 4.2 (1.1) 4.2 (3.4–4.9) 
 Other 0.0   
Kidney tumors 446 3.6 (0.9–8.0) 13.2 (7.4) 15.0 (2.7–20.0) 
Liver tumors 117 10.4 (1.0–29.7) 3.3 (0.8) 3.3 (2.7–3.8) 
Bone tumors 332 18.3 (10.6–28.1) 8.1 (8.0) 4.2 (1.2–24.9) 
 Osteosarcoma 165 13.8 (5.5–25.9) 7.6 (10.1) 2.3 (1.2–24.9) 
 Ewing 159 22.0 (10.0–38.7) 8.5 (7.3) 4.2 (1.7–21.8) 
 Other 97.6 (0.0–382.7) 8.8 8.8 (8.8–8.8) 
Germ cell tumors 171 15.6 (6.2–29.2) 3.0 (4.1) 1.8 (0.2–12.0) 
Soft tissue sarcoma 418 11.7 (6.0–19.3) 7.5 (6.6) 5.8 (0.2–24.5) 
Not elsewhere specified 319 9.6 (3.8–18.0) 6.5 (5.3) 4.9 (0.0–13.3) 
Primary cancer diagnosisTime to SMN (years)
TypeTotalSIR (95% CI)Mean (SD)Median (rangea)
Total for all cancers 7,920 9.9 (8.6–11.4) 8.6 (6.0) 7.3 (0.0–24.9) 
Leukemia 2,428 8.4 (6.1–10.9) 8.9 (6.2) 8.3 (0.3–22.7) 
 Acute lymphoblastic 1,944 7.7 (5.4–10.4) 9.1 (6.2) 8.3 (0.3–22.7) 
 Acute myeloid 363 8.6 (2.7–17.7) 10.8 (6.2) 10.8 (2.2–17.5) 
 Other 121 20.2 (6.4–41.7) 5.4 (6.3) 3.5 (0.6–16.3) 
Lymphoma and reticuloendothelial 1,044 11.3 (7.8–15.3) 10.0 (7.0) 11.6 (0.0–23.8) 
 Hodgkin lymphoma 317 15.7 (9.4–23.5) 12.6 (6.1) 12.6 (2.1–23.8) 
 Non-Hodgkin lymphoma 437 12.1 (6.4–19.6) 7.6 (7.4) 3.0 (1.2–21.2) 
 Other 290 3.6 (0.7–8.9) 3.8 (3.6) 4.2 (0.0–7.1) 
CNS 1,897 9.6 (6.9–12.7) 8.7 (5.2) 8.9 (0.3–20.3) 
 Astrocytoma 706 6.1 (3.1–10.0) 11.0 (5.5) 11.5 (1.6–20.3) 
 Medulloblastoma 316 16.8 (7.2–30.4) 5.4 (4.4) 3.9 (1.5–14.8) 
 Other CNS 875 11.4 (7.1–16.9) 8.5 (4.7) 9.2 (0.3–18.8) 
Sympathetic nervous system 748 11.2 6.3–17.6) 8.4 (5.7) 5.6 (1.3–18.2) 
 Neuroblastoma 542 15.1 (8.0–24.4) 9.0 (5.9) 6.2 (1.3–18.2) 
 Retinoblastoma 205 4.2 (0.4–12.1) 4.2 (1.1) 4.2 (3.4–4.9) 
 Other 0.0   
Kidney tumors 446 3.6 (0.9–8.0) 13.2 (7.4) 15.0 (2.7–20.0) 
Liver tumors 117 10.4 (1.0–29.7) 3.3 (0.8) 3.3 (2.7–3.8) 
Bone tumors 332 18.3 (10.6–28.1) 8.1 (8.0) 4.2 (1.2–24.9) 
 Osteosarcoma 165 13.8 (5.5–25.9) 7.6 (10.1) 2.3 (1.2–24.9) 
 Ewing 159 22.0 (10.0–38.7) 8.5 (7.3) 4.2 (1.7–21.8) 
 Other 97.6 (0.0–382.7) 8.8 8.8 (8.8–8.8) 
Germ cell tumors 171 15.6 (6.2–29.2) 3.0 (4.1) 1.8 (0.2–12.0) 
Soft tissue sarcoma 418 11.7 (6.0–19.3) 7.5 (6.6) 5.8 (0.2–24.5) 
Not elsewhere specified 319 9.6 (3.8–18.0) 6.5 (5.3) 4.9 (0.0–13.3) 

aSome malignances are identified less than 36 days apart (0.1 of a year) and hence the time to develop SMN is shown. Subsequent development of basal cell or squamous cell skin cancers was not included in the SIR calculations.

Close Modal

or Create an Account

Close Modal
Close Modal